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Abstract
Background: Escherichia coli, the main bacteria found in recurrent urinary tract infections (UTI), is now frequently
resistant to several currently used antibiotic treatments making new solutions essential. In this study, we evaluated
the association propolis and proanthocyanidins type A to reduce bacterial anti-adhesion activity of E. coli on
urothelial cells.
Results: This first double-blind, randomized, cross-over human trial included 5 volunteers that followed 6 different
regimens with or without variable doses of cranberry and propolis with a washout period of at least 1 week
between each regimen. Urine samples were collected at 0 h, 4-6 h, 12 h and 24 h after cranberry plus propolis or
placebo capsule consumption. In vivo urinary bacterial anti-adhesion activity was assessed with a bioassay (a
human T24 epithelial cell-line assay) and an in vivo Caenorhabditis elegans model. HPLC-PDA-MS was used to
detect propolis and cranberry compounds in urine. Bioassays indicated significant bacterial anti-adhesion activity in
urine collected from volunteers who had consumed cranberry plus propolis powder compared to placebo (p <
0.001). This inhibition was clearly dose-dependent, increasing with the amount of PACs and propolis equivalents
consumed in each regimen. Results suggested that propolis had an additional effect with PACs and prevent a
bacterial anti-adhesion effect over 1 day. An in vivo model showed that the E. coli strain presented a reduced
ability to kill C. elegans after their growth in urine samples of patients who took cranberry plus propolis capsules.
HPLC confirmed that propolis is excreted in urine.
Conclusions: This study presents an alternative to prevent recurrent UTI. Administration of PACs plus propolis once
daily offers some protection against bacterial adhesion, bacterial multiplication and virulence in the urinary tract,
representing an interesting new strategy to prevent recurrent UTI.
Background
Urinary tract infections (UTIs) are a widespread pro-
blem [1,2] whose recurrence is common in women,
resulting in considerable morbidity, multiple antibiotic
treatments and increased expenditures. Recently, uro-
pathogenic Escherichia coli (UPEC), the major pathogen
involved in these infections, acquired new resistance
mechanisms against b-lactams and fluoroquinolones
usually used to treat UTIs, leading to therapeutic dead-
lock of these frequent infections [3-10]. Therefore, new
strategies to prevent or treat UTIs are essential.
Recent evidence suggested that ingestion of cranber-
ries (Vaccinium macrocarpon Ait.) has been used for
prevention of UTI [11-13]. A recent systematic review
concluded that there is some positive clinical evidence
that consumption of cranberry juice can reduce the
number of symptomatic UTIs in women over a 12-
month period [12]. Research showed that consuming
cranberry products may prevent adhesion of E. coli
strains to the uroepithelium [14-16], notably multidrug
resistant strains [17], thus interfering with this
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any medium, provided the original work is properly cited.important initial step in the infection process [18]. The
proanthocyanidins (PACs) in cranberry, in particular the
A-type linkages, have been implicated as important inhi-
bitors of primarily P-fimbriated E. coli adhesion to uroe-
pithelial cells in vitro [13,19-21] and ex vivo [22,23].
Only cranberry juice with A-type PACs prevented bac-
terial adhesion, and molecular weight of PACs could
potentially impact the bacterial anti-adhesion activity.
Indeed, Foo et al. [20] showed that the active com-
pounds consisted predominantly of epicatechin units
with mainly degree of polymerization of 4 and 5 con-
taining at least one A-type linkage. Thus, the active
components in cranberry should be type-A oligomeric
procyanidins.
Propolis is a resinous material collected by bees from
exudates and buds of plants, then mixed with wax and
bee enzymes. Propolis’s antimicrobial activities are well
documented against different bacteria [24]. In vitro pro-
polis may act directly on microorganisms, and in vivo it
may stimulate the immune system, activating the killing
of bacteria. Propolis may show additional effects with
antimicrobial drugs (fluoroquinolones and b-lactams).
The objective of this study was to evaluate the associa-
tion of proanthocyanidins and propolis concerning bac-
terial anti-adhesion activity, to evaluate additional
dosage regimes and collection time-periods following
ingestion of the propolis and PACs-standardized cran-
berry powder.
Results
Effects detected by ex vivo assays
For PACs regimen, ex vivo epithelial cell adhesion assay
indicated highly significant reductions in bacterial adhe-
sion to T24 cells compared to placebo (p < 0.001) fol-
lowing the consumption of cranberry dosages containing
60 mg of PACs (Table 1). An adhesion index (AI) corre-
sponding to the mean number of adherent bacteria per
cell for 100 cells was calculated. The AI of bacteria
grown in urine samples collected after consumption of
cranberries with 60 mg PACs was significantly lower
than AI following the dose with placebo (p < 0.001).
The analysis also confirmed a time dependent-effect,
with maximum effect at 6 h compared to 24 h with 60
mg of PACs (p < 0.001) (Table 1).
For PACs plus propolis regimens, there was a dose-
dependent decrease in bacterial adhesion with cranberry
and propolis intake. The AI of bacteria grown in urine
samples collected after consumption of cranberry with
60 mg PACs and 192 mg propolis was significantly
lower than the AI following the dose with 60 mg PACs
and 170 mg propolis in urine collected at 12 h (p <
0.001). Moreover, there was a time-dependent effect. AI
of bacteria in urine collected at 6 h and 24 h was signifi-
cantly different following all regimens (p < 0.001),
except for 120 mg PACs and 340 mg propolis. For this
last regimen, the AI at 24 h remained significantly low
(AI median < 4) compared to the other regimens (p <
0.001).
Reduction of E. Coli virulence
T h em e a ns u r v i v a lt i m e( L T 5 0 )f o rw o r m sw a ss i g n i f i -
cantly increased to 5-6 days with E. coli g r o w ni nu r i n e
samples collected after cranberry or cranberry plus pro-
polis intake compared to LT50 for strains grown in
urine samples collected after placebo intake (3-4 days)
(p < 0.001) (Table 2). In urine collected after 6 h, no dif-
ference was detected between the virulence of E. coli
strain grown in urine collected after consumption of
PAC and propolis. However, there was a significant
decrease of LT50 with E. coli g r o w ni nu r i n es a m p l e s
collected after the intake of 120 mg PACs and 340 mg
of propolis after 24 h compared to all other regimens at
the same time (p < 0.001).
The number of E. coli CFU within the nematode gut
varied around 10
5-10
6 bacteria per worm for each strain
72 h after ingestion without significant difference (Table
3) confirming ingestion and proliferation of E. coli iso-
lates in the C. elegans intestine.
Table 1 Urinary bacterial adhesion to T24 cells expressed as Adhesion Index (AI) following consumption of increasing
doses of cranberry powder of proanthocyanidins (PACs) with or without propolis vs. placebo. The results are
representative of at least three independent trials
AI Median [Range]
PAC* (mg) - 36 60 60 60 72 90 120 144
Propolis (mg) - - - 170 192 - 255 340 -
4-6 h 21.5 [15-28] 10.5 [5-16] 4.7 [0-13] 3.0 [0-8] 3.5 [0-10] 5.9 [1-11] 2.1 [0-7] 1.3 [0-6] 2.5 [1-6]
12 h 22.5 [16-30] 14.4 [8-19] 12.6 [5-18] 13.7 [5-25] 7.5 [0-14] 5.9 [1-9] 2.9 [15-5] 1.8 [0-6] ND
24 h 22.3 [15-29] 16.0 [10-22] 21.5 [15-26] 17.1 [12-29] 18.5 [10-25] 14.5 [2-25] 17.4 [10-25] 3.5 [0-10] 9.9 [2-15]
Reference This study [17, 23] This study This study This study [17,23] This study This study [23]
*Expressed as vanillin-H2SO4 equivalents
Range of values are indicated into [square brackets]
ND not determined
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and metabolites in capsules and urine
In the capsules, the content of A-type proanthocyanidins
oligomers (dimers and trimers) expressed as procyanidin
A2 equivalents were 1 mg per capsule. In urine, no A-
type proanthocyanidin (neither in native form or meta-
bolised) was detected.
Concerning the potential active compounds from
propolis, we focused on galangin and pinocembrin, the
two main flavonoids found in propolis extracts from
various origins [25]. Their content in capsules was
found to be 1.41 mg per capsule. Free forms of galan-
gin and pinocembrin were present in very low amounts
in urine indicating that these compounds are excreted
mainly in a conjugated form. The time course of the
concentration of the free forms are shown in Table 4.
The concentration of the conjugates of pinocembrin in
urine was relatively constant during the first 12 h, and
reached their highest level 24 h after administration. In
contrast, the conjugates of galangin in urine were max-
imal 4-6 h after administration, and appeared to be
maintained during the next collecting times. In addi-
tion, pinocembrin seems to be excreted more effi-
ciently than galangin since the ratio galangin/
pinocembrin was higher in capsules than in urine (data
not shown).
Discussion
The increasing resistance of E. coli, bacteria most fre-
quently isolated during UTI to diverse antibiotics is an
international public health problem [7-10]. The very
common recurrence of UTI in women requires new
antibiotic treatments, promotes the emergence of new
mechanisms of resistance, inducing a vicious circle.
Finding new ways to prevent and/or treat these infec-
tions is essential. A number of strategies minimizing
antibiotic exposure have been used attempting to pre-
vent recurrent UTI. This study shows the effect of pro-
polis and cranberry (Vaccinium macrocarpon) in ex vivo
and in vivo anti-adhesion assays.
When analysing different results obtained after cran-
berry intake by our team [17,23], we established that the
minimal PACs dose with an observed anti-adhesion
effect is 36 mg. Moreover, we could see an anti-adher-
ent effect dose and time-dependent inversely propor-
tional to the PACs dose. This study shows that the
dose-dependent and time-dependent effects are also
observed when propolis was added to PACs (Table 1).
Table 2 In vivo kinetics of killing of C.elegans infected by E. coli grown in urine samples after consumption of the
different proanthocyanidins plus propolis regimens.
Strains PACs mg Propolis mg Collection time LT50 LT100 p
T0 vs. others test 1 vs. test 2 test 1 vs. test 4
NECS978323 - - 0 4.2 ± 0.2 7.4 ± 0.6 NA
test 1 60 - 4-6 h 6.5 ± 0.1 11.5 ± 0.5 < 0.001 NS
60 - 12 h 5.6 ± 0.2 9.5 ± 0.5 < 0.001 NS
60 - 24 h 4.2 ± 0.2 7.3 ± 0.7 NS NS
test 2 60 170 4-6 h 6.0 ± 0.1 11.3 ± 0.7 < 0.001 NS
60 170 12 h 5.5 ± 0.2 9.3 ± 0.7 < 0.001 NS
60 170 24 h 5.0 ± 0.2 7.8 ± 0.8 NS NS
test 3 60 192 4-6 h 6.1 ± 0.1 11.2 ± 0.8 < 0.001
60 192 12 h 5.5 ± 0.2 9.5 ± 0.5 < 0.001
60 192 24 h 5.3 ± 0.2 8.5 ± 0.5 0.02
test 4 90 255 4-6 h 6.3 ± 0.3 11.3 ± 0.7 < 0.001 NS
90 255 12 h 5.3 ± 0.3 9.5 ± 0.5 < 0.001 NS
90 255 24 h 5.8 ± 0.2 9.0 ± 1.0 < 0.001 < 0.001
test 5 120 340 4-6 h 6.0 ± 0.1 11.8 ± 0.8 < 0.001
120 340 12 h 6.2 ± 0.2 11.8 ± 0.8 < 0.001
120 340 24 h 6.3 ± 0.3 11.5 ± 0.5 < 0.001
test 6 - - 4-6 h 4.1 ± 0.2 7.2 ± 0.8 NS
- - 12 h 3.9 ± 0.1 7.0 ± 0.5 NS
- - 24 h 4.2 ± 0.3 7.3 ± 0.7 NS
OP50 - - - 7.5 ± 0.5 13.3 ± 0.7 < 0.001
The results are representative of at least three independent assays. OP50 is an avirulent E. coli strain used as control of the vitality of worms. E. coli NECS978323
was the strain used in the study. It was used as control (without treatment)
NS not significant
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was clearly noted. At 60 mg PACs and 170 mg of pro-
polis, no supplementary effect was observed on AI com-
pared to the consumption of 60 mg PACs alone.
However, with 192 mg of propolis, a significant anti-
adhesion effect is observed at 12 h (p < 0.001) for the
same PACs content. With 120 mg of PACs and 340 mg
of propolis a nycthemeral effect was clearly noted: the
AI observed at 24 h is significantly higher than the AI
detected for 144 mg PACs alone (p < 0.001). An addi-
tional anti-adherence action of PACs plus propolis is
observed, especially since the amount of absorbed PACs
is important.
We could speculate that in addition to the anti-adhe-
sion activity of PACs, propolis killed the bacteria,
decreasing the number of adherent bacteria and
facilitating the activity of PACs. The PACs contained in
cranberry inhibit E. coli adhesins notably against P-fim-
briae [15,20]. Adhesion is the first step of bacterial viru-
lence, ensuring survival and establishing replication. To
demonstrate the effect of PACs on bacterial virulence,
we used an in vivo killing nematode model validated by
different teams [17,26,27]. This nematode lives in soil
and eats environmental bacteria. It is a simple and easy
to handle model that can be used to evaluate the viru-
lence of bacterial pathogens. It is increasingly being
used to study host-pathogen interactions and has helped
identify basic evolutionarily conserved pathways asso-
ciated with microbial pathogenesis. In particular, this
has revealed important factors of the host response with
remarkable parallels in higher organisms. This organ-
ism’s short (2-3-weeks) life span facilitates host-bacteria
interaction analysis, offering an ideal compromise
between complexity and tractability. We determined
that the reduced ability of E. coli strain to kill worms
correlates with the consumption of cranberry plus pro-
polis capsules. Bacteria grown in the urine of individuals
consuming cranberry capsules was not able to adhere to
worms, thus leading to a reduced killing of the worms
despite the presence and proliferation of E. coli strain in
the C. elegans intestine. E. coli were localized within the
Table 3 Evaluation of the number of bacteria within the C.elegans digestive tract.
Strains PACs mg Propolis mg Collection time Median CFU [range]/nematodes after 72 h
NECS978323 - - 0 8.1 × 10
5 [7.0-9.3 10
6]
test 1 60 - 4-6 h 3.3 × 10
5 [2.5-4.0 10
6]
60 - 12 h 3.5 × 10
5 [2.1-5.0 10
6]
60 - 24 h 5.2 × 10
5 [4.4-6.1 10
6]
test 2 60 170 4-6 h 4.4 × 10
5 [4.0-4.8 10
6]
60 170 12 h 5.1 × 10
5 [4.8-5.4 10
6]
60 170 24 h 6.0 × 10
5 [4.9-7.2 10
6]
test 3 60 192 4-6 h 2.3 × 10
5 [2.0-3.8 10
6]
60 192 12 h 4.8 × 10
5 [4.2-5.4 10
6]
60 192 24 h 3.0 × 10
5 [2.5-3.5 10
6]
test 4 90 255 4-6 h 2.7 × 10
5 [1.0-4.2 10
6]
90 255 12 h 4.3 × 10
5 [3.5-5.1 10
6]
90 255 24 h 3.7 × 10
5 [3.2-4.0 10
6]
test 5 120 340 4-6 h 2.5 × 10
5 [1.9-3.0 10
6]
120 340 12 h 3.8 × 10
5 [2.2-5.4 10
6]
120 340 24 h 1.8 × 10
5 [1.0-3.1 10
6]
test 6 - - 4-6 h 6.0 × 10
5 [4.9-7.2 10
6]
- - 12 h 4.5 × 10
5 [3.9-5.1 10
6]
- - 24 h 7.1 × 10
5 [6.8-7.5 10
6]
OP50 - - - 6.8 × 10
5 [6.0-7.5 10
6]
After 72 h of infection, the C. elegans were washed and ground, and dilutions of the resulting suspension were plated on selective media. The number of CFU
per worm of the different strains alone or in combination was calculated. Three replicates were performed for each bacterial combination. E. coli NECS978323
was the strain used in the study. It was used as control (without treatment). No statistical difference could be demonstrated
Range of values are indicated into [square brackets]
Table 4 Time courses of contents of pinocembrin and
galangin in b-glucuronidase/sulfatase treated urine
collected after intake of capsules containing cranberry
and propolis
4-6 h 12 h 24 h
Pinocembrin (mg/L) 0.83 0.71 1.85
Galangin (mg/L) 0.19 0.09 0.14
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due to an inability to establish infection and loss of viru-
lence. In our in vivo experiment we again demonstrated
the additional action of PACs and propolis: a significant
decrease of LT50 with E. coli g r o w ni nu r i n es a m p l e s
collected after the intake of 120 mg PACs and 340 mg
of propolis observed after 24 h compared to all other
regimens over the same time, even for 144 mg PACs.
In our study we evaluated the presence of the main pro-
polis flavonoids (galangin and pinocembrin) and PACs in
capsules and urine samples by HPLC-PDA-MS. Currently
there is no universally accepted standard method for
quantification of cranberry PACs in products [28]. Quanti-
fication of PACs using colorimetric methods (DMAC
reagent, European Phamacopeae, Bate-Smith, vanillin
reagent) can lead to erroneous and unreproducible results,
absolutely not specific to the type of linkage of proantho-
cyanidins units (A-or B-type). Since many of these meth-
ods were used to determine the total PACs content in the
capsules used in the published clinical studies, little is
known about the specific A-type PACs content. In the
present study, we analysed the metabolites of the admini-
strated cranberry and propolis in urine before and after
treatment with b-glucuronidase/sulfatase. No PACs were
detected. This result, in agreement with literature [29],
lacks evidence that PACs may be biotransformed to
unique biologically active urinary metabolites, or even
reach the urine intact as dimers or trimers. Indeed, little is
known about the metabolic route of A-type PACs in
humans, especially if they are degraded in the gut, and/or
not assimilated in any quantity, and do not reach the urin-
ary tract intact. Because the putative active proanthocyani-
dins are possibly not absorbed and/or may be metabolized
before reaching the urinary tract, it is probable that other
cranberry compounds or their metabolites are active. Con-
versely, we demonstrated the presence of metabolites of
propolis in urine samples collected at various times after
administration of capsules containing cranberry and pro-
polis. Pinocembrin and galangin were present in urine,
which suggests that these two compounds are absorbed in
the blood and excreted as glucuronide and/or sulfo-conju-
gates. Their high concentrations in urine collected 24 h
after capsule administration could be responsible for the
observed effects. The antibacterial activities of these two
metabolites are part of our ongoing research. A recent
study showed that galangin isolated from Alpinia offici-
narum Hance have the potential to reverse bacterial resis-
tance to b-lactam antibiotics against penicillin-resistant
Staphylococcus aureus [30].
The main limitation of this study is the use of ex vivo
experiments to observe the effect. Further human trials
are needed to correlate the level of ex vivo anti-adhesion
activity with the prevention of clinical UTI.
Conclusions
Administration of PACs-standardized cranberry plus
propolis powder could offer a protection against bacter-
ial adhesion in the urinary tract and could represent an
additional means to help prevent infections.
Methods
Chemicals
Procyanidin A2 was purchased from Extrasynthèse
(France). b-glucuronidase/sulfatase, galangin and pino-
cembrin were purchased from Sigma-Aldrich (France).
Other chemicals were of HPLC grade.
The propolis extract used in this study is an hydroal-
coholic extract of blended propolis from various origins
(China, Europa) mixed with carob in a proportion (60/
40, w/w). This extract was standardized to contain 2%
galangin.
The cranberry extract was obtained by purification of
the polyphenolic fraction of a cranberry juice, and was
standardized to contain 20% A-type proanthocyanidins.
Bacterial strains
An uropathogenic E. coli strain previously isolated from
a patient with UTI (NECS978323) [17] with P-fimbriae
papG and type-1 pili was utilized. To allow the direct
observation of adherent bacteria by fluorescence micro-
scopy, NECS978323 was genetically modified to express
green fluorescent protein [31].
Healthy volunteers
Even if cranberry is a supplement food, the study has
been approved by our local research ethic committee
(South Mediterranean III) and has been conducted
according to the principles expressed in the Declaration
of Helsinki. Five healthy volunteers with normal diets
(25-48 years of age) were included in this double-blind,
randomised, placebo-controlled and cross-over study.
Exclusion criteria included antibiotic use within 6
months prior to the study, pregnancy, known allergy or
intolerance to cranberry/propolis products, routine con-
sumption of any food supplements consisting of vita-
mins, minerals or trace elements. All volunteers signed
informed consent. Throughout the study, volunteers
were instructed not to alter their dietary or lifestyle
h a b i t s .H o w e v e r ,d u r i n gt he capsule consumption,
volunteers were told to avoid all Vaccinium-containing
foods, drinks and supplements.
Ex vivo and in vivo protocol
The study used cranberry powder capsules, cranberry
and propolis powder capsules and placebo capsules
composed of colloidal silica, magnesium stearate, cellu-
lose and gelatin. The capsule dosages were standardized,
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method) in cranberry powder alone or associated with
42.5 mg of propolis and/or 48 mg of propolis. A propo-
lis-only capsule was not tested, as propolis alone has no
anti-adhesion activity [24]. To avoid confusion, all PACs
dosages reported in this paper were expressed as vanil-
lin-H2SO4 equivalents. Data from previous studies cited
in this article [17,23] were obtained using the Old-
DMAC method. In order to make the results more read-
able, these data were converted to vanillin-H2SO4
equivalents, while multiplying the Old-DMAC values by
a factor of 2, which is generally well-accepted.
Each volunteer received successively six regimens
(always 8 capsules) distributed in random order, consist-
ing of: (1) 4 capsules of cranberry and 4 capsules of pla-
cebo; (2) 8 capsules of placebo; (3) 4 capsules of
cranberry plus propolis (at 42.5 mg) and 4 capsules of
placebo; (4) 4 capsules of cranberry plus propolis (at 48
mg) and 4 capsules of placebo; (5) 6 capsules of cran-
berry plus propolis (at 42.5 mg) and 2 capsules of pla-
cebo; (6) 8 capsules of cranberry plus propolis (at 42.5
mg); with a washout period of at least 1 week between
each regimen. Volunteers consumed the capsules in the
morning at 8:00. The first urine samples were collected
between 12:00-14:00 following capsule consumption and
then pooled. The second urine samples were collected
at 20:00. The third collections were made the following
morning (8:00). Control urine samples were collected at
the beginning of the study, prior to consuming the cap-
sules. Remaining samples were centrifuged at 4000 g for
15 min., sterilized by filtration (0.45 μm), and stored at-
20°C.
Bacterial anti-adhesion assays
In the ex vivo urine assays, bacterial adhesion was evalu-
ated using the human T24 epithelial cell-line (ATCC
HTB-4). The technology was developed using fluores-
cent NECS978323 to enhance detection of strain adhe-
sion as previously described [23]. An adhesion index
(AI) corresponding to the mean number of adherent
bacteria per cell for 100 cells was calculated. This index
was expressed as the mean of at least three independent
assays.
Nematode killing assay
The Caenorhabditis elegans test is based upon the capa-
city of pathogens ingested by nematodes to infect and
kill [17]. The survival nematodes fed on E. coli strain is
an indirect marker of their potential virulence. This
assay was carried out as described by Lavigne et al. [17]
using Fer-15 mutant line. At least three replicates
repeated 5 times were performed for NECS978323
strain. Lethal Time 50% (LT50) and death (LT100) cor-
responded to time required to kill 50% and 100% of the
nematode population, respectively. The number of bac-
teria within the C. elegans digestive tract was carried
out as described [17].
HPLC-PDA-MS analysis of propolis and cranberry phenolic
compounds in capsules and urine
The main propolis flavonoids (galangin and pinocembrin)
and cranberry PACs (A-type procyanidins) in capsules
and urine samples were analysed by HPLC-PDA-MS
(Agilent Technologies). For capsules analysis, 1 mg of
powder was dissolved in 1 ml of 50% aqueous MeOH
and the solution was filtered (0.45 μm) before HPLC ana-
lysis. For the urine sample analysis, 2 ml of urine was
extracted by shaking for one hour with 5 ml of ethyl acet-
ate (2 times). The two ethyl acetate solutions were com-
bined, evaporated to dryness and the residue re-
suspended in 200 μl of 0.1% formic acid in 50% aqueous
MeOH before HPLC analysis. Conjugates were identified
on the basis of enzymatic hydrolysis with glucuronidase
(5000 units of b-glucuronidase and 40 units of sulfatase).
HPLC separation of samples was performed using a
Prontosil C18 reverse phase column (250 mm×4 mm, 5
μm particle size). Chromatographic data were acquired
with a photo-diode array detector set at 260 and 280 nm,
coupled with an Esquire 3000 plus MS (Bruker Daltonics,
Germany) equipped with an electro-spray ionization
(ESI) source. Identification was based on the MS and
MS/MS spectra collected over the chromatographic
peaks and their comparison with spectra of standards
(pinocembrin, galangin, procyanidin A2).
Statistical analysis
The quantitative variables were described by median
values, range and mean, as well as standard deviation.
Comparisons between different regimens were evaluated
using a two-way ANOVA procedure. The normality of
the distribution was checked in each class by the Sha-
piro-Wilks test. A Student-Newman-Keuls Test evalu-
ated the statistical difference between each pair of
groups. The entire survival curves in nematode killing
assays were compared using a Cox regression comparing
the timing of mortality between treatments. A value of p
≤ 0.05 given by the SAS
®/ETS software (version 8.1;
SAS Institute Inc, Cary, NC, USA) was considered sta-
tistically significant.
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